646 related articles for article (PubMed ID: 26642234)
1. Single versus combination immunotherapy drug treatment in melanoma.
Grimaldi AM; Marincola FM; Ascierto PA
Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
3. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
4. Advances in immunotherapy for melanoma.
Redman JM; Gibney GT; Atkins MB
BMC Med; 2016 Feb; 14():20. PubMed ID: 26850630
[TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
6. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in melanoma: Recent advances and future directions.
Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.
Simeone E; Ascierto PA
J Immunotoxicol; 2012; 9(3):241-7. PubMed ID: 22524673
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
[TBL] [Abstract][Full Text] [Related]
10. [Advances in Immunotherapy of Malignant Melanoma].
Krajsová I
Klin Onkol; 2017; 30(Supplementum3):40-44. PubMed ID: 29239191
[TBL] [Abstract][Full Text] [Related]
11. The safety of nivolumab for the treatment of metastatic melanoma.
O'Reilly A; Larkin J
Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab use for the treatment of advanced melanoma.
Specenier P
Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of patients with metastatic melanoma.
Yu Z; Si L
Chin Clin Oncol; 2017 Apr; 6(2):20. PubMed ID: 28482673
[TBL] [Abstract][Full Text] [Related]
15. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
Tanvetyanon T; Gray JE; Antonia SJ
Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
[TBL] [Abstract][Full Text] [Related]
16. CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Buchbinder EI; Desai A
Am J Clin Oncol; 2016 Feb; 39(1):98-106. PubMed ID: 26558876
[TBL] [Abstract][Full Text] [Related]
17. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
[TBL] [Abstract][Full Text] [Related]
20. Combination Controversies: Checkpoint Inhibition Alone or in Combination for the Treatment of Melanoma?
Warner AB; Postow MA
Oncology (Williston Park); 2018 May; 32(5):228-34. PubMed ID: 29847853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
